Vera Therapeutics Inc’s recently made public that its PRESIDENT AND CEO Fordyce Marshall unloaded Company’s shares for reported $0.73 million on Jan 08 ’25. In the deal valued at $41.74 per share,17,500 shares were sold. As a result of this transaction, Fordyce Marshall now holds 143,603 shares worth roughly $ 4.19 million.
Then, MARSHALL FORDYCE bought 17,500 shares, generating $736,750 in total proceeds.
Before that, Fordyce Marshall sold 17,500 shares. Vera Therapeutics Inc shares valued at $753,680 were divested by the PRESIDENT AND CEO at a price of $43.07 per share. As a result of the transaction, Fordyce Marshall now holds 85,942 shares, worth roughly $2.51 million.
Wolfe Research initiated its Vera Therapeutics Inc [VERA] rating to an Outperform in a research note published on February 04, 2025; the price target was $49. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. Wells Fargo began covering VERA with “an Overweight” recommendation on November 21, 2024. Scotiabank started covering the stock on October 16, 2024. It rated VERA as “a Sector outperform”.
Price Performance Review of VERA
On Tuesday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock jump 6.26% to $29.18. Over the last five days, the stock has lost -18.67%. Vera Therapeutics Inc shares have fallen nearly -31.00% since the year began. Nevertheless, the stocks have fallen -33.88% over the past one year. While a 52-week high of $51.61 was reached on 01/06/25, a 52-week low of $25.99 was recorded on 02/14/25. SMA at 50 days reached $39.22, while 200 days put it at $39.91.
Levels Of Support And Resistance For VERA Stock
The 24-hour chart illustrates a support level at 27.58, which if violated will result in even more drops to 25.97. On the upside, there is a resistance level at 30.07. A further resistance level may holdings at 30.95. The Relative Strength Index (RSI) on the 14-day chart is 29.85, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.97%. Stochastics %K at 14.11% indicates the stock is a buying.
The most recent change occurred on January 25, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $26 price target.
